Additional file 1 of Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer

Additional file 1: Table S1. Summary of the datasets included in the analysis. All samples were taken from triplenegative breast cancer patients before initiating neoadjuvant chemotherapy. T taxane, A anthracycline, F fluorouracil, C cyclophosphamide, E epirubicin, FNA fine needle aspiration, NACT neoadjuvant chemotherapy. Figure S1. Prognostic value of the TSP signature in patients with triple-negative breast cancer in the METABRIC dataset. A Receiver operating characteristic (ROC) curve showing the performance of the Notch TSP signature in predicting relapse-free survival in triple-negative breast cancer patients (n = 157). B Kaplan‒Meier survival curves showing the association between the signature’s predictions and relapse-free survival in the same set of patients. C Kaplan‒Meier survival curves demonstrating the association of each individual pair and relapse-free survival in the same set of patients. ‘p’ denotes the log-rank p value.